Drug intelligence / Profile preview

autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch)

Development stage: Unknown
Lead developer: Fred Hutchinson Cancer Center
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Autologous transduced hematopoietic cells developed by Fred Hutchinson Cancer Center is an experimental ex vivo gene therapy for the treatment of HIV-associated Hodgkin and non-Hodgkin lymphoma. The therapy involves the collection of a patient's own peripheral blood stem cells, which are then genetically modified using a lentiviral vector to express a gene conferring HIV resistance and a mutant form of the O6-methylguanine-DNA methyltransferase (MGMT P140K) gene. Following high-dose chemotherapy and autologous transplantation of these modified cells, patients receive treatment with O6-benzylguanine (O6BG) and carmustine (BCNU). The MGMT P140K mutation protects the modified cells from the toxic effects of this combination, allowing for the in vivo enrichment of the HIV-resistant cell population. This approach aims to reconstitute the immune system with cells that are refractory to HIV infection while simultaneously treating the underlying lymphoma.

Other names: MGMT P140K-transduced HSCsHIV-resistant hematopoietic stem cell therapyautologous transduced hematopoietic cells-Fred Hutchinson Cancer Center-HIV-associated lymphoma

Beyond the preview

Go deeper on autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous MGMT P140K-transduced hematopoietic stem cells (Fred Hutch).

Explore the full profile